405 related articles for article (PubMed ID: 26871511)
1. Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-Activation.
Kanzaki H; Mukhopadhya NK; Cui X; Ramanujan VK; Murali R
Monoclon Antib Immunodiagn Immunother; 2016 Feb; 35(1):1-11. PubMed ID: 26871511
[TBL] [Abstract][Full Text] [Related]
2. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
3. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options.
Burnett JP; Korkaya H; Ouzounova MD; Jiang H; Conley SJ; Newman BW; Sun L; Connarn JN; Chen CS; Zhang N; Wicha MS; Sun D
Sci Rep; 2015 Nov; 5():15821. PubMed ID: 26522776
[TBL] [Abstract][Full Text] [Related]
5. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
Ma C; Zuo W; Wang X; Wei L; Guo Q; Song X
Oncol Rep; 2013 Feb; 29(2):812-8. PubMed ID: 23229346
[TBL] [Abstract][Full Text] [Related]
8. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
9. Plumbagin Suppresses the Invasion of HER2-Overexpressing Breast Cancer Cells through Inhibition of IKKα-Mediated NF-κB Activation.
Kawiak A; Domachowska A
PLoS One; 2016; 11(10):e0164064. PubMed ID: 27727280
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.
Singh S; Shi Q; Bailey ST; Palczewski MJ; Pardee AB; Iglehart JD; Biswas DK
Mol Cancer Ther; 2007 Jul; 6(7):1973-82. PubMed ID: 17620428
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells.
Mao Y; Zhang Y; Qu Q; Zhao M; Lou Y; Liu J; huang O; Chen X; Wu J; Shen K
Mol Biosyst; 2015 Apr; 11(4):1029-40. PubMed ID: 25648538
[TBL] [Abstract][Full Text] [Related]
12. NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.
Bailey ST; Miron PL; Choi YJ; Kochupurakkal B; Maulik G; Rodig SJ; Tian R; Foley KM; Bowman T; Miron A; Brown M; Iglehart JD; Debajit KB
Mol Cancer Res; 2014 Mar; 12(3):408-420. PubMed ID: 24319068
[TBL] [Abstract][Full Text] [Related]
13. Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis.
Bist P; Leow SC; Phua QH; Shu S; Zhuang Q; Loh WT; Nguyen TH; Zhou JB; Hooi SC; Lim LH
Oncogene; 2011 Jul; 30(28):3174-85. PubMed ID: 21383699
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional repression of HER2 by ANO1 Cl
Fujimoto M; Inoue T; Kito H; Niwa S; Suzuki T; Muraki K; Ohya S
Biochem Biophys Res Commun; 2017 Jan; 482(1):188-194. PubMed ID: 27838298
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
16. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
17. PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.
Stanley J; Klepczyk L; Keene K; Wei S; Li Y; Forero A; Grizzle W; Wielgos M; Brazelton J; LoBuglio AF; Yang ES
Breast Cancer Res Treat; 2015 Apr; 150(3):569-79. PubMed ID: 25833211
[TBL] [Abstract][Full Text] [Related]
18. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
[TBL] [Abstract][Full Text] [Related]
19. Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation.
Tse AK; Wan CK; Shen XL; Yang M; Fong WF
Biochem Pharmacol; 2005 Nov; 70(10):1443-57. PubMed ID: 16181613
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway.
Ciucci A; Gianferretti P; Piva R; Guyot T; Snape TJ; Roberts SM; Santoro MG
Mol Pharmacol; 2006 Nov; 70(5):1812-21. PubMed ID: 16908599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
